Exploration of targeted anti-tumor therapy

Keyphrases

Publications

volume 5, number 3, 2024

Vladislava V Pipiya, Zarema E Gilazieva, Shaza S Issa, Albert Anatolyevich Rizvanov, Valeriya Vladimirovna Solovyeva
Comparison of primary and passaged tumor cell cultures and their application in personalized medicine. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Francesca Di Pressa, Fabiana Perrone, Anna Benini, Frank Lohr, Marcello Tiseo, Alessio Bruni
Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Moslem Jafarisani, S Ali Hashemi, Nassim Faridi, Mir F Mousavi, S Zahra Bathaie
Cadmium nanocluster as a safe nanocarrier: biodistribution in BALB/c mice and application to carry crocin to breast cancer cell lines. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Vanessa Patel, Sandra Casimiro, Catarina Abreu, Tiago Barroso, Rita Teixeira de Sousa, Sofia Torres, Leonor Abreu Ribeiro, Gonçalo Nogueira-Costa, Helena Luna Pais, Conceição Pinto, Leila Costa, Luís Costa
DNA damage targeted therapy for advanced breast cancer. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Yiwen Zhou, Jingjing Li, Jieer Ying
Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Francesca Di Pressa, Fabiana Perrone, Anna Benini, Frank Lohr, Marcello Tiseo, Alessio Bruni
Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Shehna Sharaf, Sreelekshmi S, Saikant Regidi, Abi Santhosh Aprem, Rajmohan Gopimohan, Lakshmi S
Evaluation of molecular effects associated with apoptosis, tumour progression, angiogenesis and metastasis by a novel combination of drugs with ormeloxifene in triple negative breast cancer cells. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Shihao Shang, Ming Gao, Kepu Liu, Maoxin Lv, Jie Zhang, Dongen Ju, Di Wei, Zelong Sun, Pinxiao Wang, Jianlin Yuan, Zheng Zhu
Landscape of targeted therapies for advanced urothelial carcinoma. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Elena Trevisi, Cristiana Sessa, Ilaria Colombo
Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Aram A Musaelyan, Ekaterina M Anokhina, Alina I Turdubaeva, Natalia V Mitiushkina, Anastasia N Ershova, Anna D Shestakova, Aigul R Venina, Evgeny N Imyanitov, Sergey V Orlov
Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS -mutated metastatic intrahepatic cholangiocarcinoma: a case report. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Giulia Pretelli, Kleida Mati, Lucia Motta, Anastasios Stathis
Antibody-drug conjugates combinations in cancer treatment. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Vladislava V Pipiya, Zarema E Gilazieva, Shaza S Issa, Albert Anatolyevich Rizvanov, Valeriya Vladimirovna Solovyeva
Comparison of primary and passaged tumor cell cultures and their application in personalized medicine. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Moslem Jafarisani, S Ali Hashemi, Nassim Faridi, Mir F Mousavi, S Zahra Bathaie
Cadmium nanocluster as a safe nanocarrier: biodistribution in BALB/c mice and application to carry crocin to breast cancer cell lines. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Fabio Campodonico, Luca Foppiani, Vittoria Campodonico, Carlo Introini
Practical implications of androgen receptor inhibitors for prostate cancer treatment. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Evgeny N Imyanitov, Elena V Preobrazhenskaya, Sergey V Orlov
Current status of molecular diagnostics for lung cancer. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Abhilasha Sood, Arpit Mehrotra, Ujjawal Sharma, Diwakar Aggarwal, Tejveer Singh, Moyad Shahwan, Ammar Abdulrahman Jairoun, Isha Rani, Seema Ramniwas, Hardeep Singh Tuli, Vikas Yadav, Manoj Kumar
Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Arpita Sahu A, Aditi Venkatesh, Aman Snehil, Abhishek Mahajan, Amit Kumar Janu, Ayushi Sahay, Shridar Epari
Imaging of supratentorial ependymomas with radio-pathological correlation. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Elena Trevisi, Cristiana Sessa, Ilaria Colombo
Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Shehna Sharaf, Sreelekshmi S, Saikant Regidi, Abi Santhosh Aprem, Rajmohan Gopimohan, Lakshmi S
Evaluation of molecular effects associated with apoptosis, tumour progression, angiogenesis and metastasis by a novel combination of drugs with ormeloxifene in triple negative breast cancer cells. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Jutatip Panaampon, Seiji Okada
Promising immunotherapeutic approaches for primary effusion lymphoma. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Jutatip Panaampon, Seiji Okada
Promising immunotherapeutic approaches for primary effusion lymphoma. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Stefano Lucà, Marina Accardo, Severo Campione, Renato Franco
Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Chouaib Salem
Selected meeting abstracts of 2nd International Conference on Contemporary Oncology. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Fabio Campodonico, Luca Foppiani, Vittoria Campodonico, Carlo Introini
Practical implications of androgen receptor inhibitors for prostate cancer treatment. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Nicola Normanno, Vincenza Caridi, Angelo Paolo Dei Tos, Antonio Avallone, Fortunato Ciardiello, Carmine Pinto
Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity? Exploration of targeted anti-tumor therapy 5 (3) (2024)
Arpita Sahu A, Aditi Venkatesh, Aman Snehil, Abhishek Mahajan, Amit Kumar Janu, Ayushi Sahay, Shridar Epari
Imaging of supratentorial ependymomas with radio-pathological correlation. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Nithiyanandan Ravi, Parul Gupta, Amanjit Bal, Kuruswamy Thurai Prasad, Mandeep Garg, Rakesh Kapoor, Navneet Singh
Chemotherapy related changes in cfDNA levels in squamous non-small cell lung cancer: correlation with symptom scores and radiological responses. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Shihao Shang, Ming Gao, Kepu Liu, Maoxin Lv, Jie Zhang, Dongen Ju, Di Wei, Zelong Sun, Pinxiao Wang, Jianlin Yuan, Zheng Zhu
Landscape of targeted therapies for advanced urothelial carcinoma. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Vanessa Patel, Sandra Casimiro, Catarina Abreu, Tiago Barroso, Rita Teixeira de Sousa, Sofia Torres, Leonor Abreu Ribeiro, Gonçalo Nogueira-Costa, Helena Luna Pais, Conceição Pinto, Leila Costa, Luís Costa
DNA damage targeted therapy for advanced breast cancer. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Yiwen Zhou, Jingjing Li, Jieer Ying
Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Evgeny N Imyanitov, Elena V Preobrazhenskaya, Sergey V Orlov
Current status of molecular diagnostics for lung cancer. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Stefano Lucà, Marina Accardo, Severo Campione, Renato Franco
Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Giulia Pretelli, Kleida Mati, Lucia Motta, Anastasios Stathis
Antibody-drug conjugates combinations in cancer treatment. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Nicola Normanno, Vincenza Caridi, Angelo Paolo Dei Tos, Antonio Avallone, Fortunato Ciardiello, Carmine Pinto
Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity? Exploration of targeted anti-tumor therapy 5 (3) (2024)
Aram A Musaelyan, Ekaterina M Anokhina, Alina I Turdubaeva, Natalia V Mitiushkina, Anastasia N Ershova, Anna D Shestakova, Aigul R Venina, Evgeny N Imyanitov, Sergey V Orlov
Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS -mutated metastatic intrahepatic cholangiocarcinoma: a case report. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Abhilasha Sood, Arpit Mehrotra, Ujjawal Sharma, Diwakar Aggarwal, Tejveer Singh, Moyad Shahwan, Ammar Abdulrahman Jairoun, Isha Rani, Seema Ramniwas, Hardeep Singh Tuli, Vikas Yadav, Manoj Kumar
Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective. Exploration of targeted anti-tumor therapy 5 (3) (2024)

volume 5, number 4, 2024

Amatta Mirandari, Helen Parker, Margaret Ashton-Key, Benjamin Stevens, Renata Walewska, Kostas Stamatopoulos, Dean J Bryant, David G Oscier, Jane Gibson, Jonathan C Strefford
The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Simon Gray, Nuria Santamaria, Anna Olsson-Brown
Immune checkpoint inhibitor-induced cholangitis-a three-case series. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Ken Akao, Yuko Oya, Takaya Sato, Aki Ikeda, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Masashi Kondo, Kazuyoshi Imaizumi
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Shayan Smani, Vinaik Sundaresan, Soum D Lokeshwar, Ankur U Choksi, Jeffrey Carbonella, Joseph Brito, Joseph Renzulli, Preston C Sprenkle, Michael S Leapman
Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Palmiro Poltronieri
Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Mohan Hingorani, Hannah Stubley
Oligometastatic esophageal cancer cured by systemic therapy combined with radiotherapy to primary tumor and metastasis (metastasis-directed therapy)-small case series. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Donna Zhuang, David Zhang, Stephen Riordan
Hepatobiliary complications of immune checkpoint inhibitors in cancer. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Sutatip Pongcharoen, Nongphanga Kaewsringam, Poorichaya Somaparn, Sittiruk Roytrakul, Yaowapa Maneerat, Komsak Pintha, Supachai Topanurak
Immunopeptidomics in the cancer immunotherapy era. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Abhishek Mahajan, Gurukrishna B, Shweta Wadhwa, Ujjwal Agarwal, Ujjwal Baid, Sanjay Talbar, Amit Kumar Janu, Vijay Patil, Vanita Noronha, Naveen Mummudi, Anil Tibdewal, J P Agarwal, Subhash Yadav, Rajiv Kumar Kaushal, Ameya Puranik, Nilendu Purandare, Kumar Prabhash
Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Minira Aslanova, Eun-Mi Yu, Jeanny B Aragon-Ching
The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC). Exploration of targeted anti-tumor therapy 5 (4) (2024)
Suraj Narayanan Chembukavu, Andrew J Lindsay
Therapy-induced senescence in breast cancer: an overview. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Robert C Hsu, Zhaohui Liao Arter, Darin Poei, David J Benjamin
A narrative review on perioperative systemic therapy in non-small cell lung cancer. Exploration of targeted anti-tumor therapy 5 (4) (2024)

volume 5, number 5, 2024

Zachary Hamel, Sierra Sanchez, David Standing, Shrikant Anant
Role of STAT3 in pancreatic cancer. Exploration of targeted anti-tumor therapy 5 (5) (2024)
Zachary Hamel, Sierra Sanchez, David Standing, Shrikant Anant
Role of STAT3 in pancreatic cancer. Exploration of targeted anti-tumor therapy 5 (5) (2024)